Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Ovarian Cancer

Charlie Gourley

查理·古尔利

PhD, FRCP

🏢University of Edinburgh / Edinburgh Cancer Research Centre(爱丁堡大学/爱丁堡癌症研究中心)🌐UK

Professor of Medical Oncology; Director, Nicola Murray Centre for Ovarian Cancer Research肿瘤内科学教授;尼古拉·默里卵巢癌研究中心主任

50
h-index
2
Key Papers
3
Awards
2
Key Contributions

👥Biography 个人简介

Charlie Gourley, PhD, FRCP is a Professor of Medical Oncology at the University of Edinburgh and Director of the Nicola Murray Centre for Ovarian Cancer Research. He is internationally recognized for pioneering the concept of 'BRCAness' — the functional HRD phenotype beyond BRCA mutation — and for investigating PARP inhibitor response mechanisms in ovarian cancer.

Share:

🧪Research Fields 研究领域

Ovarian Cancer卵巢癌
PARP InhibitorsPARP抑制剂
BRCAnessBRCA样特征
Homologous Recombination Deficiency同源重组缺陷
Molecular Biomarkers分子生物标志物

🎓Key Contributions 主要贡献

BRCAness and Homologous Recombination Deficiency in Ovarian Cancer

Pioneered clinical research into BRCAness as a functional HRD phenotype predicting PARP inhibitor sensitivity beyond germline BRCA mutation, reshaping patient selection strategies for PARP inhibitor therapy.

Mechanisms of PARP Inhibitor Response and Resistance

Led translational studies dissecting mechanisms of PARP inhibitor sensitivity and acquired resistance in high-grade serous ovarian cancer, informing combination strategies to overcome resistance.

Representative Works 代表性著作

[1]

Olaparib versus placebo in patients with BRCA1 or BRCA2 mutations and recurrent high-grade serous ovarian carcinoma (Study 19 translational analysis)

The Lancet Oncology (2014)

Translational analysis of BRCAness biomarkers from Study 19, demonstrating that HRD phenotype beyond germline BRCA mutation can predict olaparib benefit.

[2]

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1)

The Lancet Oncology (2017)

Defined genomic scar HRD score as a predictive biomarker for rucaparib activity, establishing HRD-based patient selection beyond BRCA mutation status.

🏆Awards & Recognition 奖项与荣誉

🏆British Gynaecological Cancer Society Young Investigator Award
🏆CRUK Scotland Institute Prize for Translational Oncology
🏆Scottish Government Chief Scientist Office Research Award

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 查理·古尔利 的研究动态

Follow Charlie Gourley's research updates

留下邮箱,当我们发布与 Charlie Gourley(University of Edinburgh / Edinburgh Cancer Research Centre)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment